Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers. [electronic resource]
Producer: 20190603Description: 109-116 p. digitalISSN:- 1090-2104
- Animals
- Antineoplastic Agents -- administration & dosage
- CRISPR-Cas Systems
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- DNA Helicases -- genetics
- Female
- Gene Knockout Techniques
- Humans
- Isoquinolines -- administration & dosage
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- Mutation
- Myeloid Cell Leukemia Sequence 1 Protein -- antagonists & inhibitors
- Nuclear Proteins -- genetics
- Oxidative Phosphorylation -- drug effects
- Proteolysis
- Sulfonamides -- administration & dosage
- Transcription Factors -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.